INmune Bio Inc. (NASDAQ: INMB), a late-stage biotechnology company focused on inflammation and immunology, today announced ...

Extends Partnership with One of Australia’s Largest Utility Providers and Establishes Pathway to Multi-Million-Dollar Annual Revenue Contribution ...

The Base Shelf Prospectus is available under the Company’s profile on SEDAR+ at www.sedarplus.ca and, upon determination of the final terms of the Offering, and the signing of an agency agreement ...

Home Affairs expands Smart ID banking services Home Affairs Minister Dr Leon Schreiber says the department has expanded access to Smart ID replacement services by 47% within two months through its new ...

Avacta Therapeutics (AIM: AVCT, “the Company”, “Avacta”), a clinical stage biopharmaceutical company developing pre|CISION, a tumor-activated oncology delivery platform today published its unaudited ...

After more than $1.7 billion in dealmaking and a string of Phase 1 starts in 2026, prostate, pancreatic, and other historically immunotherapy-resistant solid tumors are suddenly among the busiest batt ...

NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES. ANY FAILURE TO COMPLY WITH THIS RESTRICTION MAY CONSTITUTE A VIOLATION OF U.S. SECURITIES LAW ...

Again Jesus spoke to them, saying, “I am the light of the world. Whoever follows me will not walk in darkness, but will have ...

Avacta Therapeutics (AIM: AVCT, "the Company", "Avacta"), a clinical stage biopharmaceutical company developing pre|CISION, a tumor-activated ...

Atossa Therapeutics, Inc. ("Atossa" or the "Company"), a clinical-stage biopharmaceutical company developing novel therapies in oncology and other areas of significant unmet medical need, today ...

Olema Pharmaceuticals awaits Phase 3 breast cancer data in fall 2026, with $505M in cash to fund catalysts. Learn why OLMA ...

Read all about the best betting apps in the UK as our expert offers his data-driven ranking of the best bookmaker apps on ...